Le Lézard
Classified in: Health
Subjects: MAV, CFG

/R E M I N D E R -- Media Advisory - Prime Minister's itinerary for Wednesday, March 13, 2024/


OTTAWA, ON, March 12, 2024 /CNW/ -

Note: All times local

Calgary, Alberta


8:30 a.m.     

The Prime Minister will meet with the Premier of Alberta, Danielle Smith.




Note for media:


  • Pooled coverage

10:20 a.m.   

The Prime Minister will make a dental care announcement. A media availability will follow.




Notes for media:


  • Open coverage
  • Media are asked to arrive no later than 9:30 a.m.
  • Media interested in participating can contact [email protected] for details.

1:40 p.m.

The Prime Minister will meet with seniors.




Note for media:


  • Pooled coverage

This document is also available at https://pm.gc.ca

SOURCE Prime Minister's Office


These press releases may also interest you

at 07:43
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the...

at 07:15
KFSHRC Revolutionizes Patient Care with Pioneering Experience Ambassadors Program
King Faisal Specialist Hospital & Research Centre (KFSHRC) is redefining patient engagement and care through its pioneering Experience Ambassadors Program. This initiative empowers selected employees to become ?ambassadors' from various...

at 07:00
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
In Phase Ia clinical study, GZR4 demonstrated favorable safety and tolerability profiles in healthy subjects, maintaining a stable glucose-lowering effect for up to one week with a single administration.In Phase Ib clinical study, patients with Type...

at 06:00
BioInvent and Transgene's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments
BioInvent International (STO:BINV)Preliminary data presented at ESMO 2024 demonstrate BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT-001 was able to...

at 05:00
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials;...

at 04:20
Pfizer's BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Pfizer Inc. today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for patients with BRAF V600E-mutant...

More news about Health...


News published on and distributed by: